LUPIN LTD. Q1 FY27 Results

Lupin's consolidated Q1 FY27 revenue came in at ₹8,276.89 Cr, up 32.0% YoY and 10.7% QoQ, comfortably ahead of Street estimates that had clustered around ₹6,300-7,096 Cr (Uniresearch's 37-analyst consensus pegged it at ₹6,632 Cr). Consolidated PBT of ₹2,017.36 Cr grew a sharper 42.5% YoY (+4.6% QoQ), while consolidated PAT (total, including minority interest) of ₹1,416.98 Cr rose a more modest 16.0% YoY but slipped 3.5% QoQ — still beating the Street's PAT estimate range of ₹927-1,179 Cr (Uniresearch: ₹1,053 Cr).

The gap between PBT growth (+42.5%) and PAT growth (+16.0%) is a tax-base effect, not an operating slip: Q1 FY26's effective tax rate was an unusually low 13.7% (aided by a ₹296.8 Cr deferred-tax credit that quarter), versus a normalized 29.8% this quarter and 23.8% last quarter. Reported net margin consequently compresses to 17.12% from 19.24% YoY and 19.29% QoQ, even though the underlying EBITDA margin (computed consistently as PBT plus finance cost and depreciation, less other income, over operating revenue) actually improves to roughly 29.6% from 27.55% a year ago. Consolidated results also reflect the VISUfarma B.V. acquisition (concluded April 1, 2026, Euro 192.8 million/₹20,902.7 Cr consideration) consolidating for the first time, with acquisition costs booked in other expenses; per the auditors' note, a set of 17 unreviewed overseas subsidiaries posted a combined net loss of ₹241.1 Cr this quarter, which is the main reason standalone PAT (₹2,714.60 Cr) runs far ahead of consolidated PAT (₹1,416.98 Cr) — a materially different picture between the two bases that readers should note.

The stock went into the print at ₹2,385, down 3% over the past month of trading.

For context: revenue is at a 6-quarter high.

No exceptional items in the current or year-ago consolidated quarter, unlike Q4 FY26's ₹131.3 Cr exceptional expense — YoY comparison is clean and unadjusted

Consolidated basic EPS ₹30.95 vs ₹34.83 (Q4 FY26, before exceptional items) and ₹26.70 (Q1 FY26)

Against management's FY27 guidance from the last call — high-single-digit revenue growth with EBITDA margins normalizing to around 25% from FY26's record levels, amid new competition for Tolvaptan and Mirabegron — the print is broadly on track: margins are moving down toward the guided level (29.6% EBITDA margin this quarter, still above the ~25% full-year target, consistent with a gradual normalization), while the outsized 32% YoY revenue growth is aided by the VISUfarma consolidation rather than being a clean organic beat of the high-single-digit guide. No standalone press release or management commentary on the print was available at the time of this analysis; the earnings call is scheduled for August 7. The quarter's other developments — USFDA approvals for Diazepam Injection USP and Sugammadex Injection (announced July 31, 2026) and the subsidiary's licensing of oncology programs for an 82.2% stake in Kaveri Therapeutics (announced July 21, 2026) — sit alongside management's stated strategy of expanding the complex-product and biosimilar portfolio, though neither is large enough to show up in this quarter's reported numbers.

Lupin beat FY27 revenue expectations in Q1 with 32% YoY growth, but the quarter was exceptional—no Tolvaptan competition yet, old inventory masking cost inflation. Management rightly guides moderation: US drops to USD 250–280M per quarter, EBITDA margins fall 460 bps to ~25%, and PAT grew only 16% despite 32% revenue growth. Long-term pipeline (biosimilars, complex generics) is rich and specific; near-term headwinds (competitive intensity, cost pressure) are real and quantified. Fair-value case; execution on FY28+ recovery needed to re-rate higher.

Analysts pressed hard on US guidance (why 25–30% QoQ drop); management held firm, citing Q2–Q4 Tolvaptan/Mirabegron competition explicitly. On Apixaban sizing, management deferred quantification ('still sizing up'), which drew probes but no dodging. Overall tone: disciplined, not defensive; management stood by conservative FY27 guidance despite Q1 beat.

Score 8/10. Clear on product specifics and timing (Pegfilgrastim H2, Apixaban September target, 15+ filings FY27). Transparent on headwinds (Tolvaptan/Mirabegron competition, cost inflation, adjacency losses). Some deferral (Apixaban differentiation, overall FTF market sizing promised 'offline'). 16 consecutive quarters of YoY growth; met EBITDA margin guidance (25% maintained despite Q1 beat). FDA VAI status for two plants. Respiratory platform learnings advancing (Spiriva Respimat device cleared, Ellipa positive PK). VISUfarma integration on track.

Lupin enters Q1 FY2027 off a modest baseline — Q1 FY26 delivered ₹6,268 Cr in revenue — and the Street consensus expects the company to grow into the ₹6,300–7,096 Cr range. That's a narrow band by design: at the low end, it's a holding pattern; at the high end, it's a +13% YoY sprint. The difference hinges on one metric: US business uptake. Since late June, Lupin has notched five U.S. FDA approvals (Diazepam Injection, Sugammadex, Azilsartan, the Ranluspec biosimilar, and Eribulin), each representing an incremental dollar pool. The question for investors is not whether Lupin approvals it — the company has cleared that bar — but whether the launches stick and price in the way management has modeled.

Strong: Revenue lands in the ₹6,700–7,096 Cr band (double-digit YoY growth); EBITDA margin stays above 39%, signaling pricing stability on new US launches and cost discipline; US segment shows incremental contribution from Sugammadex and biosimilar ramp; domestic growth re-accelerates (low single digits at minimum). Weak: Revenue misses the ₹6,300 Cr floor, stalling at or below ₹6,200 Cr; margin compression below 37% flags execution risk on new product integration or pricing headwinds; US segment flatness despite approvals casts doubt on launch momentum and Street's Q2–Q3 trajectory assumptions.

Lupin has not yet issued formal FY27 guidance — that will likely come on the Aug 7 earnings call. However, the Street has already priced in an FY27 earnings trajectory anchored on 12–15% revenue growth and normalized 38–40% EBITDA margins, a return to pre-inflation profitability. Q1 is the reset button. If the quarter lands comfortably in the ₹6,500+ Cr zone with healthy margins, it will confirm management's internal assumptions and unlock the ₹2,400–2,700 consensus range. A miss invites a repricing of the FY27 model and tests the bull case.